Xeris Biopharma Holdings (XERS) EBITDA (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported EBITDA for 7 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 15.42% year-over-year to $5.2 million; the trailing twelve-month figure through Jun 2026 stood at $36.6 million (up 472.56% YoY), and the FY2025 full-year result was $24.9 million, up 173.99% from the prior year.
• EBITDA fell to $5.2 million in Q2 2026 per XERS's latest filing, from $7.9 million in the prior quarter.
• Across five years, EBITDA topped out at $16.8 million in Q4 2025 and bottomed at -$29.1 million in Q1 2022.
• Historically, EBITDA has averaged -$6.8 million across 5 years, with a median of -$9.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA slumped 162.43% in 2024, then jumped 898.99% in 2025.
• Over 5 years, EBITDA stood at -$15.2 million in 2022, then jumped by 35.13% to -$9.8 million in 2023, then soared by 117.06% to $1.7 million in 2024, then surged by 898.99% to $16.8 million in 2025, then slumped by 69.16% to $5.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $5.2 million, $7.9 million, and $16.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.